GEN Exclusives

More »

GEN News Highlights

More »
Feb 15, 2007

Champions Biotechnology Obtains BPU Patents

  • Champions Biotechnology obtained  patent rights encompassing two benzoylphenylurea (BPU) sulfur analog compounds that they report has shown potent activity against prostate and pancreatic cancer cell lines.

    BPU is an antimitotic inhibitor that targets microtubule-associated protein tau deficient tumors, a common feature of solid tumors. These inhibitors have performed better than Docetaxel (Taxotere) in direct-patient xenograft models of pancreatic cancer, according to the company.

    The company, in exchange for 550,000 restricted shares of its common stock, was assigned all the rights in the U.S. and in foreign countries to the applications for these inhibitors developed at Johns Hopkins University.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?